ClinicalTrials.gg
Sign In

Choroidal Neovascularization clinical trials

The registry lists 214 studies for Choroidal Neovascularization across more than 10 countries. 12 are recruiting or about to start. 95 of them are mainly about Choroidal Neovascularization (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Polypoidal Choroidal Vasculopathy too: 260 studies, 18 open.

Get an email when these change. Save the Choroidal Neovascularization studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
142
Terminated
23
Status unknown
21
Withdrawn
9
Active, not recruiting
7
Not yet recruiting
6

Phase

Phase 2
62
Phase 3
49
Phase 1
35
Phase 4
24

Where

United States
88
France
26
Italy
26
Germany
19
Spain
18
Australia
16

Who runs them

Novartis Pharmaceuticals (21) · National Eye Institute (NEI) (11) · Novartis (8) · Notal Vision Ltd. (7) · Medical University of Vienna (6) · Johns Hopkins University (5) · GlaxoSmithKline (5) · Chengdu Kanghong Biotech Co., Ltd. (4)

What is being tested here

Drugs under test in Choroidal Neovascularization studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Faricimab216
EYE201222
Ranibizumab01243
Bevacizumab0714
Brolucizumab069
Aflibercept017
Verteporfin026
Pazopanib004
Triamcinolone Acetonide024
Triamcinolone024

Drug classes tested here Angiogenesis inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 7 · Corticosteroids 7 · mTOR inhibitors 4

Coming up

4phase 3 studies under way
4studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 6
AgeWomenMen
100 (0%)0 (0%)
182 (33%)2 (33%)
302 (33%)2 (33%)
402 (33%)2 (33%)
506 (100%)6 (100%)
656 (100%)6 (100%)
756 (100%)6 (100%)
856 (100%)6 (100%)

Across all 214 studies, recruiting or not: 7% stop at 75 or younger and 5% at 65; 10% take children; 0% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Choroidal Neovascularization studies take

Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 327 mo23–35 · 15 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 214. Browse all 214 → or search them.